# CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

> **NCT03504488** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioAtla, Inc.** · enrollment: 132 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Triple Negative Breast Cancer
- Melanoma
- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** CAB-ROR2-ADC
- **BIOLOGICAL:** PD-1 inhibitor

## Key facts

- **NCT ID:** NCT03504488
- **Lead sponsor:** BioAtla, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-27
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03504488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03504488, "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03504488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*